South Korea’s Samsung Biologics will perform large scale manufacturing services for San Fran company Vir Biotechnology’s SARS-CoV-2 monoclonal antibody (mab) programme under a new manufacturing agreement.
Vir’s lead SARS-CoV-2 mAb development candidates, VIR-7831 and VIR-7832, have demonstrated high affinity for the SARS-CoV-2 spike protein and are highly potent in neutralizing SARS-CoV-2 in live-virus cellular assays.
Vir plans to proceed directly into a phase 2 clinical trial within the next three to five months. Today’s agreement builds on Vir’s previously announced manufacturing agreement with WuXi Biologics and its letter of intent with Biogen.
Under $362 million deal, Samsung Biologics is expected to commence its manufacturing as early as October with the first engineering run, with potential commercial batches to be manufactured starting in 2021 in Plant 3.
The parties will continue to negotiate additional terms in a definitive agreement and will use best efforts to execute a definitive agreement before July 31, 2020.